Please be aware that HIV medicines, including EDURANT®, INTELENCE®, and PREZISTA®, do not cure HIV infection, do not reduce the risk of transmission of HIV to others, and should always be taken in combination with other HIV medicines prescribed by your healthcare professional.

- Follow your healthcare professional’s directions regarding the use of these medicines
- Discuss any questions you have about your treatment, including side effects and health status, with your healthcare professional
- Products are not shown at actual size

PROTEASE INHIBITORS (PIs)

- Darunavir/cobicistat: PREZISTA®
- Elvitegravir/cobicistat: Vitekta®
- Dolutegravir: Tivicay®
- Raltegravir: Isentirtra®
- Atazanavir sulfate/cobicistat: Evotaz™
- Nelfinavir mesylate: Viracept®
- Ritonavir: Norvir®
- Fosamprenavir calcium: Lexiva®
- Lopinavir/ritonavir: Kaletra®
- Saquinavir mesylate: Invirase®
- Crixivan®
- Tipranavir: Aptivus®, Cobicistat

ENTRY INHIBITORS

- Maraviroc: Fuzeon®

INTEGRASE INHIBITORS

- Efavirenz: Sustiva®
- Nevirapine: Viramune®/Viramune XR®
- Rilpivirine: Edurant®
- Emtricitabine: Emtriva®
- Tenofovir disoproxil fumarate: Viread®

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)

- Efavirenz: Sustiva®
- Nevirapine: Viramune®/Viramune XR®
- Nevirapine

NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (N[t]RTIs)

- Lamivudine: Combivir®, Emtriva®, Epivir®, Zerit®, Trizivir®, Abacavir sulfate: Ziagen®, Atripla®
- Didanosine: Videx®
- Lamivudine‡: Zidovudine §
- Tenofovir disoproxil fumarate §: Viread®, Truvada®, Complera®, Triumeq®
- Abacavir sulfate/lamivudine/zidovudine: Epzicom®
- Lamivudine/abacavir sulfate/zidovudine: Combivir®
- Zidovudine§: Abacavir sulfate/ lamivudine/zidovudine: Trizivir®
- Lamivudine/zidovudine: Combivir®, Emtriva®, Epivir®, Zerit®, Trizivir®, Atripla®, Complera®, Triumeq®

PHARMACOKINETIC ENHANCER

- Cobicistat

MULTICLASS SINGLE-TABLET REGIMENS

- A pill containing a complete medicine regimen
- A pill containing a combination of N[t]RTIs
- A pill containing a non-N[t]RTI

*Indications, safety, and efficacy of these products may vary. Please refer to the full Prescribing Information or Patient Information of each medication for more details.

Please use our most current page for Indication and Important Safety Information for EDURANT®, INTELENCE®, PREZCOBIX™, and PREZISTA®.

Janssen Therapeutics, Division of Janssen Products, LP

© 2015 Janssen Therapeutics, Division of Janssen Products, LP 02/15 014546-150205
Evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, or pruritus) should be managed according to clinical judgment. The benefits and risks of continued therapy should be carefully considered when evaluating the patient’s condition.

This indication is based on safety and efficacy analyses through 96 weeks from 2 randomized, double-blind, active-controlled, Phase 3 studies in treatment-experienced adult patients with HIV-1 infection and CD4+ cell counts $<$ 200 cells/mm$^3$.

**Important Safety Information**

**Contraindications**

- **Contraindication to darunavir**: The use of darunavir with at least one component of PREZCOBIX™ has resulted in cases of severe and/or fatal drug-induced liver injury, including autopsy-confirmed cases of hepatic necrosis. Therefore, coadministration of darunavir with at least one component of PREZCOBIX™ is contraindicated.

- **Contraindication to cobicistat**: The use of cobicistat with at least one component of PREZCOBIX™ has resulted in cases of severe and/or fatal drug-induced liver injury. Therefore, coadministration of cobicistat with at least one component of PREZCOBIX™ is contraindicated.

**Warnings and Precautions**

- **Drug Interactions**: Drug interactions may occur with coadministration of EDURANT®, including clinical comments.

- **Depression Disorders**: Severe depression disorders, defined as severe, clinical, or major depression, arising in patients treated with protease inhibitors, have been reported in rare cases in patients with or without a history of depression before starting treatment. If severe depression disorders develop, treatment should be interrupted until clinical judgment indicates that the depression has resolved.

- **Hepatotoxicity**: Severe hepatotoxicity has been reported in patients with underlying hepatic disease, including those with Child-Pugh Class B or C. Continue monitoring LFTs in patients with hepatic disease, including those with Child-Pugh Class B or C.

- **Autoimmune disorders**: Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported in the setting of HIV treatment. Therefore, monitoring of LFTs should be continued in all patients treated with EDURANT®.

- **Drug-drug interactions**: Drug-drug interactions may be affected by coadministration of EDURANT® with other drugs. Please refer to the full prescribing information for the interaction information of the coadministered drug(s).

**Contraindications**

- **Contraindication to EDURANT®**: EDURANT® should not be used in patients taking rifampin. EDURANT® should not be used in combination with NNRTIs.

- **Contraindication to cobicistat**: The use of cobicistat with at least one component of PREZCOBIX™ has resulted in cases of severe and/or fatal drug-induced liver injury. Therefore, coadministration of cobicistat with at least one component of PREZCOBIX™ is contraindicated.

**Warnings and Precautions**

- **Drug Interactions**: Drug interactions may occur with coadministration of EDURANT®, including clinical comments.

- **Depression Disorders**: Severe depression disorders, defined as severe, clinical, or major depression, arising in patients treated with protease inhibitors, have been reported in rare cases in patients with or without a history of depression before starting treatment. If severe depression disorders develop, treatment should be interrupted until clinical judgment indicates that the depression has resolved.

- **Hepatotoxicity**: Severe hepatotoxicity has been reported in patients with underlying hepatic disease, including those with Child-Pugh Class B or C. Continue monitoring LFTs in patients with hepatic disease, including those with Child-Pugh Class B or C.

- **Autoimmune disorders**: Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported in the setting of HIV treatment. Therefore, monitoring of LFTs should be continued in all patients treated with EDURANT®.

- **Drug-drug interactions**: Drug-drug interactions may be affected by coadministration of EDURANT® with other drugs. Please refer to the full prescribing information for the interaction information of the coadministered drug(s).

**Important Points**

- **Contraindication to PI**: EDURANT® should be used with caution in patients with severe hepatic impairment (Child-Pugh Class C).

- **Depression Disorders**: Severe depression disorders, defined as severe, clinical, or major depression, arising in patients treated with protease inhibitors, have been reported in rare cases in patients with or without a history of depression before starting treatment. If severe depression disorders develop, treatment should be interrupted until clinical judgment indicates that the depression has resolved.

- **Hepatotoxicity**: Severe hepatotoxicity has been reported in patients with underlying hepatic disease, including those with Child-Pugh Class B or C. Continue monitoring LFTs in patients with hepatic disease, including those with Child-Pugh Class B or C.

- **Autoimmune disorders**: Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported in the setting of HIV treatment. Therefore, monitoring of LFTs should be continued in all patients treated with EDURANT®.

- **Drug-drug interactions**: Drug-drug interactions may be affected by coadministration of EDURANT® with other drugs. Please refer to the full prescribing information for the interaction information of the coadministered drug(s).

**Contraindications**

- **Contraindication to darunavir**: The use of darunavir with at least one component of PREZCOBIX™ has resulted in cases of severe and/or fatal drug-induced liver injury. Therefore, coadministration of darunavir with at least one component of PREZCOBIX™ is contraindicated.

- **Contraindication to cobicistat**: The use of cobicistat with at least one component of PREZCOBIX™ has resulted in cases of severe and/or fatal drug-induced liver injury. Therefore, coadministration of cobicistat with at least one component of PREZCOBIX™ is contraindicated.

**Warnings and Precautions**

- **Drug Interactions**: Drug interactions may occur with coadministration of EDURANT®, including clinical comments.

- **Depression Disorders**: Severe depression disorders, defined as severe, clinical, or major depression, arising in patients treated with protease inhibitors, have been reported in rare cases in patients with or without a history of depression before starting treatment. If severe depression disorders develop, treatment should be interrupted until clinical judgment indicates that the depression has resolved.

- **Hepatotoxicity**: Severe hepatotoxicity has been reported in patients with underlying hepatic disease, including those with Child-Pugh Class B or C. Continue monitoring LFTs in patients with hepatic disease, including those with Child-Pugh Class B or C.

- **Autoimmune disorders**: Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported in the setting of HIV treatment. Therefore, monitoring of LFTs should be continued in all patients treated with EDURANT®.

- **Drug-drug interactions**: Drug-drug interactions may be affected by coadministration of EDURANT® with other drugs. Please refer to the full prescribing information for the interaction information of the coadministered drug(s).

**Important Points**

- **Contraindication to PI**: EDURANT® should be used with caution in patients with severe hepatic impairment (Child-Pugh Class C).

- **Depression Disorders**: Severe depression disorders, defined as severe, clinical, or major depression, arising in patients treated with protease inhibitors, have been reported in rare cases in patients with or without a history of depression before starting treatment. If severe depression disorders develop, treatment should be interrupted until clinical judgment indicates that the depression has resolved.

- **Hepatotoxicity**: Severe hepatotoxicity has been reported in patients with underlying hepatic disease, including those with Child-Pugh Class B or C. Continue monitoring LFTs in patients with hepatic disease, including those with Child-Pugh Class B or C.

- **Autoimmune disorders**: Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported in the setting of HIV treatment. Therefore, monitoring of LFTs should be continued in all patients treated with EDURANT®.

- **Drug-drug interactions**: Drug-drug interactions may be affected by coadministration of EDURANT® with other drugs. Please refer to the full prescribing information for the interaction information of the coadministered drug(s).